Allergan to buy liver drug maker Tobira in deal potentially valued at $1.7B

September 20, 2016 1:31 PM

1 0

Pharmaceutical manufacturer Allergan said Tuesday it has agreed to buy liver disease drug developer Tobira Therapeutics in a deal valued at up to about $1.7 billion.

Allergan, headquartered in Dublin, Ireland, will pay $28.35 per share in cash and “up to” $49.84 per share “that may be payable based on the successful completion of certain development, regulatory and commercial milestones,” Allergan said.

Also read: BAT offers to buy U.S. tobacco firm Reynolds in $47 billion deal

Read more

To category page